Malthe Jakobsen has been confirmed as the final driver signing for McLaren’s upcoming World Endurance Championship Hypercar project, which is scheduled to debut in 2027.
Joining McLaren’s Driver Line-up
The 23-year-old Danish driver makes the move following a four-year stint with Peugeot in the 9X8 program. At McLaren, he will be reunited with former team-mate Mikkel Jensen and join a driver roster that already features Laurens Vanthoor, Alex Lynn, Leonardo Fornaroli, and Gregoire Saucy. Team management has not yet finalized how the drivers will be split across the two three-driver entries for the Dallara-chassis MCL-HY LMDh.
Expressing his enthusiasm for the move, Jakobsen told Motorsport.com, “I am super excited to join the team, it feels unbelievable to be part of this project and this brand, in particular as it competes across WEC, F1 and IndyCar in pursuit of the Triple Crown.” He added that the organization’s history, including its 1995 Le Mans victory, makes it an honor to represent them globally, and praised the leadership of James, Richard, and Zak in building a strong group.
Reflecting on His Time with Peugeot
Speaking to Motorsport.com during the 2026 season finale weekend at Monza, Jakobsen reflected on his formative years with Peugeot. He noted that he joined the manufacturer at age 18 and experienced a crucial period of personal and professional growth surrounded by supportive colleagues.
“I arrived when I was 18 and now I’m 23; it was very important to have a group of people around me like the one Peugeot provided,” Jakobsen stated. He expressed gratitude to the team for helping shape his character and driving ability, noting that he considers himself to be at the beginning of a long career.
McLaren team principal Barclay welcomed the new addition, stating that the young Dane has proven himself to be one of endurance racing’s most exciting prospects through his speed, consistency, and technical expertise. Barclay noted that as preparations continue toward the 2027 WEC debut, Jakobsen represents a fantastic addition to the MCL-HY program.
